Efficacy of adjunctive d-Cycloserine for the treatment of schizophrenia: a systematic review and meta-analysis of randomized controlled trials
The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
D-Cycloserine is a partial agonist at the glycine site of the N-methyl-D-aspartate (NMDA) receptor. Results have been inconsistent in trials on the efficacy of D-Cycloserine in patients with schizophrenia. We examined the efficacy of D-Cycloserine against negative and cognitive symptoms (primary and co-primary outcomes). Secondary outcomes were efficacy of D-Cycloserine against positive symptoms and the examination of early treatment outcomes. A systematic literature search was carried out using following selection criteria: Population = Patients with Schizophrenia; Intervention = Trials using D-Cycloserine either as monotherapy or adjuvant therapy; Comparison = Placebo or active comparator; Outcome = Change in negative symptoms, cognitive symptoms and positive symptoms; Study design = Randomized controlled trials with parallel design. We used the Cochrane Collaboration tool for risk of bias for study quality appraisal. Effect sizes for trials were calculated separately for negative, positive and cognitive symptom dimensions using the DerSimonian-Laird random effects model. Seven studies (pooled N = 413) provided data for meta-analysis. The pooled Standardized Mean Difference (SMD) for negative, cognitive, and positive symptom change scores were - 0.32 (95% CI, - 0.75 to 0.11), - 0.05 (95% CI, - 0.91 to 0.81), and - 0.08 (95% CI, - 0.37 to 0.20), respectively. No significant improvement was noted with regard to early outcome. I 2 values for heterogeneity were 61%, 67%, and 0% for studies assessing negative, cognitive, and positive symptom ratings, respectively. D-Cycloserine did not exhibit significant efficacy in treating negative, cognitive, or positive symptoms of schizophrenia at either study-defined endpoint (4-36 weeks) or at four weeks (early outcome).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“D-cycloserine, a glycine site modulator, has been assessed over the last decade in negative, positive, and cognitive symptom domains in schizophrenia with mixed results [171]”
From Ketamine in neuropsychiatric disorders: an update (2024) · cites this paper as [171]
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Higgins, J. P. T., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A. C., et al. (2011) · BMJ · doi:10.1136/bmj.d5928 · Cited by 33,817
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000100 · Cited by 28,164
Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048
Moghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793 · cited 1×
“Hypofunction of the NMDA receptor is suggested to reduce GABAergic interneuron inhibition of cortical glutamatergic afferents; this, in turn, is suggested to increase subcortical dopamine release, predisposing to the positive symptoms of schizophrenia (Moghaddam et al. 1997; Coyle et al. 2003).”
BackgroundDanysz, W., & Parsons, C. G. (1998) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01382-6 · Cited by 649
Converging Evidence of NMDA Receptor Hypofunction in the Pathophysiology of Schizophrenia
COYLE, J. T., TSAI, G., & GOFF, D. (2003) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1300.020 · Cited by 442
Goff, D. C., Tsai, G., Levitt, J., Amico, E., Manoach, D., Schoenfeld, D. A., Hayden, D. L., McCarley, R., & Coyle, J. T. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.1.21 · Cited by 436
Cited by
Ketamine in neuropsychiatric disorders: an update
Johnston, J. N., Kadriu, B., Kraus, C., Henter, I. D., & Zarate, C. A. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-023-01632-1 · Cited by 108
de Bartolomeis, A., Vellucci, L., Austin, M. C., Simone, G. D., & Barone, A. (2022) · Biomolecules · doi:10.3390/biom12070909 · Cited by 45
Sohal, V. S. (2023) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2023.102820 · Cited by 22
Pharmacological Treatments of Negative Symptoms in Schizophrenia—An Update
Tsapakis, E.-M., Treiber, M., Mitkani, C. A., Drakaki, Z., Cholevas, A., Spanaki, C., & Fountoulakis, K. Ν. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13185637 · Cited by 20
“…not effective as an adjunctive drug to dopaminergic blocking agents such as haloperidol, risperidone, or clozapine in attenuating negative symptoms [80]; the indirect modulation of NMDARs mediated by N-methyl-glycine (sarcosine), a glycine transporter (GlyT-1) inhibitor, proved advantageous as an…”
BackgroundIUPHAR review: Moving beyond dopamine-based therapeutic strategies for schizophrenia
Moran, P. M., & Granger, K. T. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107727 · Cited by 13
Metadata
- Authors
- Kuppili, P. P., Menon, V., Sathyanarayanan, G., Sarkar, S., & Andrade, C.
- Affiliations
- Black Country Healthcare NHS Foundation Trust (GB)
- Jawaharlal Institute of Post Graduate Medical Education and Research (IN)
- All India Institute of Medical Sciences (IN)
- National Institute of Mental Health and Neurosciences (IN)
- Corresponding author
- Menon, Vikas
- ORCID
- Venue
- Journal of Neural Transmission
- Published
- 2021-01-13
- Volume
- 128
- Issue
- 2
- Pages
- 253-262
- ISSN
- 0300-9564 (ISSN-L)
- 1435-1463
- OpenAlex
- W3120509113
- Cited by
- 16
- References
- 40
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 2 · 2023: 2 · 2022: 3 · 2021: 1
- FWCI
- 0.36
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Journal of Neural Transmission (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Amino Acid Enzymes and Metabolism
- Keywords
- D-cycloserine, schizophrenia, adjunctive therapy, NMDA receptor glycine site, negative symptoms, cognitive symptoms, positive symptoms, early treatment outcomes, treatment efficacy
- MeSH terms
- Cycloserine, Drug Therapy, Combination, Humans, Schizophrenia, Antipsychotic Agents, Randomized Controlled Trials as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy of adjunctive d-Cycloserine for the treatment of schizophrenia: a systematic review and meta-analysis of randomized controlled trials. https://app.cochat.ai/papers/10.1007/s00702-020-02292-x
- The paper
- Kuppili, P. P., Menon, V., Sathyanarayanan, G., Sarkar, S., & Andrade, C. (2021). Efficacy of adjunctive d-Cycloserine for the treatment of schizophrenia: a systematic review and meta-analysis of randomized controlled trials. Journal of Neural Transmission. https://doi.org/10.1007/s00702-020-02292-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.